Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-Df-IAB2M PET in metastatic prostate cancer
NCT01923727Phase 2Completed
- Sponsor
- ImaginAb
- Start
- Aug 2013
- Primary completion
- May 2016
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
A Phase 2 trial of 89Zr-DF-IAB2M in prostate cancer (PCa), sponsored by ImaginAb. Started Aug 2013; status: completed.
02
Drugs
89Zr-DF-IAB2M
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01923727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01923727.